Back to top

Analyst Blog

Actavis, Inc. (ACT - Analyst Report) and Warner Chilcott plc recently announced that both companies have received a request from the Federal Trade Commission (FTC) for additional information regarding Actavis’ upcoming acquisition of Warner Chilcott.

As a result, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) will get extended until 30 days after Actavis and Warner Chilcott have complied with the request. This time period may be extended voluntarily by the concerned parties or terminated earlier by the FTC.

Actavis had first announced its intention to acquire Warner Chilcott in May 2013. The stock-for-stock transaction, valued at about $8.5 billion, includes the assumption of Warner Chilcott’s net debt of $3.4 billion.

The successful completion of this deal will lead to the creation of a leading global specialty pharmaceutical company with combined annual revenues of about $11 billion. The combined company will hold the third position in the US specialty pharmaceutical market with annual revenues of about $3 billion.

Actavis and Warner Chilcott continue to expect the deal to close in the second half of this year. The two companies will be combined to form a new company domiciled in Ireland where Warner Chilcott is currently incorporated.

We are positive on this deal which makes strategic and financial sense. The deal is expected to be immediately accretive. Moreover, it will provide strong operating cash flow and allow Actavis to de-lever its balance sheet. The tax rate will also be significantly below current levels.

While Actavis currently carries a Zacks Rank #3 (Hold), Warner Chilcott is a Zacks Rank #2 (Buy) stock.

Other companies that currently look well-positioned include Mylan, Inc. (MYL - Analyst Report) and Simcere Pharmaceutical Group . Both are Zacks Rank #2 stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%